128 related articles for article (PubMed ID: 12270857)
1. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance.
Sorensen MB; Collins P; Ong PJ; Webb CM; Hayward CS; Asbury EA; Gatehouse PD; Elkington AG; Yang GZ; Kubba A; Pennell DJ
Circulation; 2002 Sep; 106(13):1646-51. PubMed ID: 12270857
[TBL] [Abstract][Full Text] [Related]
2. Depot-medroxyprogesterone acetate and endothelial function before and after acute oral, vaginal, and transdermal estradiol treatment.
Torgrimson BN; Meendering JR; Kaplan PF; Minson CT
Hypertension; 2011 Apr; 57(4):819-24. PubMed ID: 21357271
[TBL] [Abstract][Full Text] [Related]
3. Trabecular bone in long-term depot-medroxyprogesterone acetate users.
Virutamasen P; Wangsuphachart S; Reinprayoon D; Kriengsinyot R; Leepipatpaiboon S; Gua C
Asia Oceania J Obstet Gynaecol; 1994 Sep; 20(3):269-74. PubMed ID: 7811192
[TBL] [Abstract][Full Text] [Related]
4. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
[TBL] [Abstract][Full Text] [Related]
5. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
6. Long-term use of contraceptive depot medroxyprogesterone acetate in young women impairs arterial endothelial function assessed by cardiovascular magnetic resonance.
Wakatsuki A; Okatani Y; Fukaya T
Circulation; 2003 May; 107(20):e197; author reply e197. PubMed ID: 12777328
[No Abstract] [Full Text] [Related]
7. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
8. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
[TBL] [Abstract][Full Text] [Related]
9. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women.
Lizarelli PM; Martins WP; Vieira CS; Soares GM; Franceschini SA; Ferriani RA; Patta MC
Contraception; 2009 Jan; 79(1):35-40. PubMed ID: 19041439
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of the therapeutic effectiveness of ethinyl oestradiol and oestrone sulphate on prolonged bleeding in women using depot medroxyprogesterone acetate for contraception. World Health Organization, Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation.
Said S; Sadek W; Rocca M; Koetsawang S; Kirwat O; Piya-Anant M; Dusitsin N; Sethavanich S; Affandi B; Hadisaputra W; Kazi A; Ramos RM; d'Arcangues C; Belsey EM; Noonan E; Olayinka I; Pinol A
Hum Reprod; 1996 Oct; 11 Suppl 2():1-13. PubMed ID: 8982739
[TBL] [Abstract][Full Text] [Related]
11. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
12. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
[TBL] [Abstract][Full Text] [Related]
13. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
Kaunitz AM
Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of depot medroxyprogesterone acetate contraception.
Mishell DR
J Reprod Med; 1996 May; 41(5 Suppl):381-90. PubMed ID: 8725700
[TBL] [Abstract][Full Text] [Related]
15. Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users.
Sereepapong W; Chotnopparatpattara P; Taneepanichskul S; Markham R; Russell P; Fraser IS
Hum Reprod; 2004 Mar; 19(3):547-52. PubMed ID: 14998949
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of Cyclofem and depot medroxyprogesterone acetate (DMPA) effects on endometrial vasculature.
Simbar M; Tehrani FR; Hashemi Z; Zham H; Fraser IS
J Fam Plann Reprod Health Care; 2007 Oct; 33(4):271-6. PubMed ID: 17925114
[TBL] [Abstract][Full Text] [Related]
17. Body weight and body composition of depot medroxyprogesterone acetate users.
Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
[TBL] [Abstract][Full Text] [Related]
18. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
Polaneczky M; Guarnaccia M; Alon J; Wiley J
Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
[TBL] [Abstract][Full Text] [Related]
19. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen.
Wakatsuki A; Okatani Y; Ikenoue N; Fukaya T
Circulation; 2001 Oct; 104(15):1773-8. PubMed ID: 11591613
[TBL] [Abstract][Full Text] [Related]
20. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
